MicroPort Endovascular (Shanghai) Co ("MicroPort® Endovascular") recently gained the registration certificate for its in-house developed Hercules™ Balloon Inflation Catheter from Brazil's National Health Surveillance Agency.

Hercules™ Balloon Inflation Catheter is indicated for enhancing the vessel wall apositioning of self-expandable graft-stent. It can effectively enhance graft-stent expansion, avoid incomplete vessel wall apositioning, eliminate aneurysm endoleak risk, and ensure precise deployment.

Hercules™ Balloon Inflation Catheter is designed to work with MicroPort® Endovascular's Hercules™ Thoracic Stent-Graft System and Hercules Bifurcated Stent-Graft System. With Hercules™ Balloon Inflation Catheter's market launch approval in Brazil, the entire serial of MicroPort® Endovascular's Hercules™ products have been launched in the local market, which will better serve the need of surgeons and further expand the company's overseas market.

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 18 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.